$70 Million Verdict Against J&J in Risperdal Trial

Largest Verdict Thus Far Against Jansen for $70 Million in Risperdal Trial According to Reuters, Janssen Pharmaceuticals, a unit of Johnson & Johnson, was hit with a $70 million verdict in a Risperdal trial last week, marking the largest verdict against Janssen thus far in this ongoing litigation. The award was handed down in the case of a 15 … [Read more...]

Amgen Pays $71 Million for Promoting Off-Label Drug Uses

Pharmaceutical Giant Amgen Pays States to Settle Illegal Promotion of Off-Label Uses for Drugs Biotech and pharmaceutical company Amgen has agreed to pay 48 states a settlement amount of $71 million after a group of attorneys general claimed the company intentionally promoted off-label uses for two of its major drugs. Amgen had been accused of … [Read more...]

Risperdal Lawsuit Ends in Win for Plaintiff, But No Damages

Jury Finds Risperdal Caused Plaintiff’s Gynecomastia, But Awards No Financial Damages On Friday, March 20th, the jury for the latest Risperdal personal injury lawsuit ruled that Johnson & Johnson failed to warn doctors and patients of the risks of using Risperdal for off-label prescriptions, which led to the plaintiff’s gynecomastia; however, … [Read more...]

Second Risperdal Victim Wins Personal Injury Trial

Autistic Alabama Man Receives $2.5 Million for Risperdal Gynecomastia Side Effect On Tuesday, February 24th, a Philadelphia jury once again ruled in favor of a Risperdal victim – this time, an autistic man from Alabama who took the antipsychotic as a teenager, and grew 46DD breasts as a side effect. Gynecomastia is a sadly common side effect in … [Read more...]

J&J Loses First Risperdal Gynecomastia Trial

Plaintiff Awarded $2.5 Million in Damages for Risperdal Gynecomastia Side-Effects In the first Risperdal gynecomastia personal injury trial for the multidistrict litigation, a Philadelphia jury has decided in favor of the plaintiff, and awarded the victim of Risperdal’s side effects $2.5 million. Risperdal was approved in 1993, launched in 1994, … [Read more...]

J&J Wins Cut in South Carolina Risperdal Judgment

J&J Successfully Gets South Carolina Risperdal Judgement - Damages Cut in Half Although Johnson & Johnson, and its subsidiary Janssen Pharmaceuticals, face thousands of Risperdal personal injury lawsuits combined in a multidistrict litigation (MDL) in Philadelphia, the companies are fighting previous penalties for off-label use in numerous … [Read more...]

Former FDA Chief Testified J&J Knew Risperdal Dangers

Ex-FDA Chief Testified in Risperdal Trial that J&J Knew About Dangerous Side Effects According to testimony in the current Risperdal trial, Johnson & Johnson knew as early as 2001 that it’s antipsychotic drug had serious, dangerous side effects, including that it could cause gynecomastia (female breast tissue growth) in young boys. Former … [Read more...]

Opening Arguments Begin in Risperdal MDL Injury Case

Risperdal MDL in Philadelphia Begins Opening Arguments On Friday, January 23rd, the Risperdal MDL (multidistrict litigation) alleging long-lasting personal injury caused by the drug Risperdal, when used for off-label purposes, began in Philadelphia. Opening arguments debated the specific personal injury claim that using Risperdal in young boys … [Read more...]

Arkansas Will Not Reconsider Risperdal Verdict

Arkansas Court Says It Will Not Reconsider Tossing Risperdal Penalty The Arkansas Supreme Court says that it will not reconsider the March 20th ruling that overturned the $1.2 billion penalty for Johnson & Johnson’s off-label marketing of Risperdal. In early April, Arkansas Attorney General Dustin McDaniel announced that he would ask the … [Read more...]

Montana Settles Risperdal Lawsuit for $5.9 Million

Janssen To Pay $5.9 Million Settlement to Montana for Misleading Ads In March of this year, Montana State Attorney General Tim Fox announced that Johnson & Johnson’s subsidiary Janssen Pharmaceuticals agreed to pay $5.9 million to settle allegations in the state regarding its antipsychotic drug, Risperdal. Like many Risperdal settlements in … [Read more...]

BestLawyers.comAVBetter Business Bureau